We’re pushing the limits of genetic medicine. And our goal is no limits.
Location: United States, Massachusetts, Cambridge
Total raised: $210M
Investors 2
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.01.2020 | Series C | $110M | - |
| 27.02.2018 | Series B | $100M | - |
Mentions in press and media 13
| Date | Title | Description |
| 09.10.2024 | City Therapeutics: $135 Million (Series A) Raised For RNAi-Based Medicine | City Therapeutics announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. And City Therapeutics aims to utilize next-generation engineering of small interfering RNAs (siRNAs) – which is the “trigger”... |
| 06.03.2024 | Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results | - |
| 12.05.2021 | GENERATION BIO CO. Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results | Durable, therapeutically relevant levels of anti-SARS-CoV-2 spike antibodies produced from the liver in a mouse model Next-generation rapid enzymatic synthesis of closed-ended DNA further increases the efficiency and scale of the manufactur... |
| 01.04.2020 | Coronavirus Business Tracker: How The Private Sector Is Fighting The Covid-19 Pandemic | Alain Mérieux, founder of BioMérieux.AFP via Getty Images |
| 12.01.2020 | Generation Bio Announces $110 Million Series C Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing. Proceeds will be used to advance the company’s two lead liver-targeted progra... |
| 10.01.2020 | Generation Bio grabs a $110M round to ramp up work on next-gen gene therapies | In 2018, Generation Bio broke cover with a $25 million series A, swiftly followed by a meatier $100 million second funding round. Now, just before the J.P. Morgan Healthcare Conference, it has grabbed its biggest yet, a $110 million series ... |
| 10.01.2020 | Generation Bio Raises $110M in Series C Financing | Generation Bio, a Cambridge, MA-based gene therapy company, closed a $110m Series C financing. The round was led by T. Rowe Price funds and accounts, with participation from Farallon, Wellington Management Company and existing investors Atl... |
| 10.01.2020 | Generation Bio Inks $110M Series C Financing | CAMBRIDGE, MA, Generation Bio announced the closing of a $110 million Series C financing. >> Click here for more funding data on Generation Bio >> To export Generation Bio funding data to PDF and Excel, click here Generat... |
| 28.02.2018 | Term Sheet — Wednesday, February 28 | THE STATE OF PRIVATE EQUITY Good morning, Term Sheet readers. Paid Content What you need to know about growing cyberattacks From ExtraHop —- In lieu of Term Sheet’s ‘5 Qs With a Dealmaker’ this week, we feature a Q&A with Hugh MacArthur... |
| 27.02.2018 | Generation Bio Raises $100M | CAMBRIDGE, MA, Generation Bio, a developer of genetic medicines, has secured $100 million in Series B financing. >> Click here for more funding data on Generation Bio >> To export Generation Bio funding data to PDF and Excel... |
Show more